Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1019 PanCAN launch
BioCentury & Getty Images

Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

With the launch of Precision Promise, pancreatic cancer is the latest indication to secure an adaptive platform trial 

With the launch of Precision Promise, pancreatic cancer is the latest indication to secure an adaptive platform trial.

Oct 17, 2020 | 1:18 AM GMT

The motivation for launching the first adaptive platform trial in pancreatic cancer is to stimulate therapeutic innovation in an indication sorely in need of new ideas. The hope of the non-profit leading the study is that by changing the economics of drug development it can engage more biopharmas, and more patients, in the process. 

On Tuesday, the Pancreatic Cancer Action Network (PanCAN) announced the long-anticipated launch of the Precision Promise master protocol trial, adding pancreatic cancer to a slowly growing list of indications being addressed with adaptive platform trials. 

The Precision Promise trial, which will be

Read the full 1507 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE